Human subjects were infected with Haemophilus ducreyi. All subjects developed papules and were randomized to treatment with a single dose of azithromycin (1 g) or ciprofloxacin (500 mg). At weekly intervals, volunteers were reinoculated with H. ducreyi, and drug concentrations were measured in peripheral blood mononuclear cells (PBMC). When papules developed, the subjects were treated with antibiotics and dismissed from the study. Eight of the ciprofloxacin-treated subjects developed papules 1 week after the initial treatment, and the ninth subject developed disease 2 weeks after treatment. The 9 azithromycin-treated subjects developed papules 4 -10 weeks (mean, 6.8) after the initial treatment (P õ .001). Azithromycin was detected in PBMC for 3 -6 weeks (mean, 4). Pre-and posttreatment lesions had histology typical of experimental chancroid or were culture positive. Azithromycin prevents experimental chancroid for nearly 2 months. These findings have implications for strategies to prevent chancroid.
Haemophilus ducreyi, the etiologic agent of chancroid, is a progress to pustules between 3 and 9 days [6] . At this dose, the papule formation rate is 95%, and the pustule formation major cause of genital ulcer disease (GUD) in many developing countries and is associated with enhanced transmission of hurate is 70% (unpublished data).
A female subject enrolled in a dose-response trial did not man immunodeficiency virus (HIV) [1 -5] . H. ducreyi facilitates HIV transmission by providing an accessible portal of develop disease after inoculations of either 30 or 45 cfu [6] . The subject subsequently recalled taking a 5-day course of entry, by promoting viral shedding, and by recruiting macrophages and CD4 cells to the skin [3, 4, 6 -8] . HIV-positive azithromycin, Ç1 month prior to challenge. Serum obtained 16 and 43 days after she had completed the course of azithromycin patients may not be reliably cured by standard antibiotic therapy for chancroid [3, 4, 9] . In a process termed ''epidemiologic contained a heat-stable substance that killed H. ducreyi. Serum obtained 6 months later had no killing activity. The subject synergy,'' GUD enhances HIV transmission, and HIV increases the duration of GUD [3, 4] . Prevention of chancroid was rechallenged 1 year later with 30 cfu and developed typical disease. We suspected that azithromycin protected the subject could have a major effect on the control of HIV transmission in areas where both diseases are endemic.
from the initial experimental challenge. H. ducreyi is highly susceptible to azithromycin, with MICs To study H. ducreyi pathogenesis, we developed an experithat range from 0.0005 to 0.004 mg/mL [11] . Azithromycin mental human model of infection in which subjects are inocutissue concentrations are generally 10 -100 times that of serum lated with bacteria on the skin of the upper arm with an allergy and persist after serum concentrations decline [12] . Fibroblasts testing device [6, 10] . An estimated delivered dose of 30 cfu concentrate azithromycin intracellularly up to 450 times that produces erythematous papules within 24 h of inoculation that of the extracellular matrix and are thought to be the primary reservoir of the drug [13] . Azithromycin is also concentrated in polymorphonuclear leukocytes and macrophages [14, 15] . On the basis of a peak tissue concentration of 3 -4 mg/mL and JID 1998;177 (June) Prevention of Chancroid Enrollment of 9 subjects in each treatment group had a 95% and to estimate the median duration of protection afforded by power to detect an 80% difference in the ability of ciprofloxacin each drug.
(90% become infected) versus azithromycin (10% become infected) to protect in the first week after therapy at a 5% significance level.
Materials and Methods
Culture and histologic analysis of biopsies. Biopsies were diHuman volunteers. Adult men and women were eligible for vided in half longitudinally. One section was semiquantitatively the study if they were healthy as determined on the basis of history, cultured for H. ducreyi as described previously [6, 10] . Results physical examination, and results of HIV serology. We excluded were expressed as colony-forming units (cfu) per gram of tissue. persons with risk factors for HIV infection or positive HIV serol-
The remaining section was fixed in formalin and embedded in ogy, previous history of chancroid, immunodeficiency disease, paraffin. After being sectioned, the tissue was stained with hematherapy with immunosuppressive medications, skin disease, a histoxylin and eosin and with anti-CD3 antibodies (Dako, Carpinteria, tory of keloid formation, or allergies to study medications; women CA) as described previously [6] . who were pregnant; and persons who had taken any antibiotic Measurement of drug concentrations. Blood was obtained within 1 month of enrollment or azithromycin within 3 months of from volunteers at enrollment and prior to each challenge. PBMC enrollment or who were currently using any drug that interacts were isolated by ficoll-hypaque gradient centrifugation, counted, with the study medications.
diluted in PBS to a density of Ç10 6 cells/mL, and frozen [6] .
Experimental human infection. H. ducreyi 35000HP (HP, hu-
Azithromycin concentrations in PBMC were determined by high man passaged) was used to inoculate the volunteers. H. ducreyi performance liquid chromatography (HPLC) with triple quadru-35000HP was expanded from a single colony recovered from a pole mass spectrometry, a proprietary method of BAS Analytics subject after 13 days of experimental infection with H. ducreyi (Shoup RE, Beato BD; unpublished data). The limit of detection 35000 [6] . Bacteria were grown in broth to mid-log phase and was 0.2 ng/mL of cell suspension. Intracellular azithromycin conprocessed exactly as described previously [6, 10] . The MICs of centrations were calculated by dividing the quantity of drug by azithromycin (0.012 mg/mL) and ciprofloxacin (0.03 mg/mL) for the estimated cell volume of PBMC in the sample. Assuming that 35000HP were determined using published methods [11] .
PBMC are comprised of 53% monocytes and 47% lymphocytes Suspensions containing Ç6 1 10 4 cfu of live or heat-killed and that a monocyte has a cell volume of 421 fL/cell and that a 35000HP were inoculated into the skin of the upper arm with an lymphocyte has a cell volume of 204 fL/cell, the estimated average allergy-testing device (Multi-Test applicator; Lincoln Diagnostics, cell volume was 315 fL/cell [16] . Decatur, IL) as described previously [6] . Two sites were inoculated Ciprofloxacin concentrations in PBMC were measured by HPLC with live bacteria, and one site was inoculated with the heat-killed with fluorescence detection [17] . The sensitivity of the assay was control. The device delivers Ç1/1000 of solutions loaded on its 10 ng/mL of cell suspension. tines to the dermis and epidermis to a depth of 1.9 mm [6] . Thus, Statistical analysis. The Kaplan-Meier method was used to the estimated delivered dose was Ç60 cfu. Subjects were assessed estimate time-to-infection ''survival'' curves for each antibiotic. 24 h later for induration, erythema, lymphadenopathy, and fever, The curves were compared using a log-rank test. McNemar's test and the inoculated areas were photographed.
was used to examine differences between pre-and posttreatment When a subject developed a papule at either of the sites that biopsy cultures within each treatment group. were inoculated with live bacteria, 1 lesion was anesthetized with 1% lidocaine containing epinephrine and biopsied with a 3-mm punch forceps. Lidocaine had no effect on H. ducreyi viability [6] .
Results
Sites inoculated with the heat-killed control were also biopsied in Chemoprophylactic effect of azithromycin versus ciproflox-4 subjects.
acin. Nineteen subjects were enrolled in the study (table 1) .
Study design and power. Throughout the study, subjects were inoculated with single preparations of live and of heat-killed bacteOne subject in the azithromycin group required antibiotics for ria within a 2-h time period. Colony counts were done on the a tooth extraction on day 7 and was removed from the analyses.
suspensions before the first subject's inoculation and immediately after the last subject's inoculation. One day after the initial inoculation, papules were biopsied, and subjects were randomized to treat- Table 1 . Demographic characteristics of subjects experimentally ment with a single dose of azithromycin (1 g) or ciprofloxacin infected with H. ducreyi and randomized to treatment with ciproflox-(500 mg). The treatment assignments were prepared by a pharmaacin or azithromycin. cist, who administered the drug. The investigators who evaluated the subjects were unaware of the treatment assignments. Once a Ciprofloxacin Azithromycin week, the subjects were inoculated with H. ducreyi and examined Characteristic (n Å 9) (n Å 9) 24 h later. The end point of the study was development of an Female 6 6 erythematous papule; 2 investigators had to agree that a site inocu- lesion was present at the site inoculated with heat-killed bacteria.
Black
At entry, all volunteers were challenged at two sites with live of 1.6 { 2.5 1 10 4 cfu/g was recovered from 3 of 9 ciprofloxacin-treated subjects. H. ducreyi was recovered from only 1 H. ducreyi and at 1 site with heat-killed H. ducreyi. In 24 h, all subjects developed erythematous papules at sites inoculated posttreatment biopsy in the azithromycin group (2.5 1 10 3 cfu/g). There were no significant differences between the prowith live bacteria, and no lesions occurred at sites inoculated with heat-killed bacteria. Thus, all subjects were susceptible to portion of pre-and posttreatment biopsy cultures that were positive for each group (ciprofloxacin, P Å 1.0; azithromycin, infection. After undergoing biopsy, subjects were randomized to receive a single dose of either azithromycin (1 g) or ci-P Å .22). Histologic analysis of lesions. Biopsy specimens obtained profloxacin (500 mg). Erythema resolved within 12 -24 h, and all lesions healed. Subjects were reinoculated with H. ducreyi before treatment and at the study end point were examined in a blinded fashion for evidence of disease. The histopathology of on the opposite arm on a weekly basis until they developed recurrent disease.
the specimens was similar in all subjects (figure 2). Epidermal micropustules, papillary dermal edema, and perivascular, periOf the 9 ciprofloxacin-treated subjects, 8 developed disease when reinoculated 1 week after treatment, and the ninth subject follicular, and interstitial dermal infiltrates composed of neutrophils and mononuclear cells were found. All specimens condeveloped disease 2 weeks after treatment ( figure 1) . Thus, ciprofloxacin did not prevent experimental infection.
tained an infiltrate of CD3 cells typical of experimental human chancroid. Four sites inoculated with heat-killed bacteria were Following reinoculation, the 9 azithromycin-treated subjects developed papules between 4 and 9 weeks after treatment (mehistologically normal. Thus, the clinical diagnosis of disease was confirmed in all subjects. dian, 7; mean { SD, 6.8 { 2.1) (figure 1). One subject who did not develop disease by day 42 withdrew. We considered Drug concentrations in PBMC. Drug was undetectable in PBMC of ciprofloxacin-treated subjects at 1 week. Azithroher to be protected from disease for 6 weeks. The difference in time to reinfection between the ciprofloxacin and azithromycin mycin was detected in PBMC for 3 -6 weeks (mean, 4; figure  3 ). The terminal elimination half-life of azithromycin was calgroups was highly significant (P õ .001).
Three of the 9 azithromycin-treated and 2 of 9 ciprofloxacinculated from the data obtained between weeks 2 and 4. When we used a noncompartmental model, the estimated half-life treated subjects reported mild gastrointestinal discomfort that resolved within 12 -24 h after drug ingestion. One subject was 181 h (7.5 days). treated with ciprofloxacin and 1 treated with azithromycin developed hypertrophic scars at their biopsy sites. Both subjects Discussion were treated with local steroid injections, and the scars have flattened.
Our study was prompted by the observation that a volunteer who had taken a 5-day course of azithromycin was protected Recovery of H. ducreyi from experimental lesions. H. ducreyi was recovered from 9 of 18 pretreatment biopsies. The from development of experimental human chancroid. Her serum had killing activity against H. ducreyi for up to 43 days. mean cfu/g ({SD) recovered was 5.2 { 2.3 1 10 3 . After drug treatment and the development of a second infection, a mean
We hypothesized that a 1-g dose of azithromycin would prevent experimental infection for Ç1 month. We found that one dose human challenge model, inoculation of Ç1 -15 cfu into the skin results in a papule formation rate of 74% [6] (unpublished of azithromycin prevented experimental disease for an average of 6.8 { 2.1 weeks. data). Inoculation of Ç30 cfu causes a papule formation rate of 95% (unpublished data). To insure that susceptible subjects In natural infection, H. ducreyi has an estimated transmission rate of 80%, but the infectious dose is unknown [2] . In the would develop infection, we chose 60 cfu as a target dose and inoculated the subjects at 2 sites. All subjects were inoculated skin cells, was probably responsible for the prolonged chemoprophylactic effect. with one preparation of live bacteria during a 2-h time period. Subjects inoculated at the beginning of the challenge period Azithromycin also has activity against Treponema pallidum, Neisseria gonorrhoeae, and Chlamydia trachomatis [11, received a mean ({SD) dose of 66.2 { 27.9 cfu, and those inoculated at the end of the challenge period received a mean 25 -28], and prophylactic use of azithromycin could have an impact on sexually transmitted diseases (STDs) other than of 27 { 16.1 cfu; therefore, all subjects were challenged with doses that were sufficient to cause infection.
chancroid. One potential drawback of azithromycin prophylaxis may be the development of resistance. Two erythromycinThe histopathology of all biopsied lesions (both pre-and posttreatment) was consistent with previously reported historesistant H. ducreyi strains were recovered in Singapore in the 1980s [29] , but recently collected clinical isolates were logic findings in the human challenge model [6, 10] . H. ducreyi was recovered from 50% of the pretreatment biopsies and 13% susceptible to erythromycin and azithromycin [21, 30] . Isolates of N. gonorrhoeae that possess the genetic locus Mtr are relaand 33% of the azithromycin and ciprofloxacin posttreatment biopsies, respectively. The limit of detection for this assay is tively resistant to macrolides [11] , and monitoring for the development of resistance in H. ducreyi and N. gonorrhoeae may Ç1.4 1 10 3 cfu. In our model, only 30 -60 cfu were inoculated into the skin, and only half of the specimen was cultured. Thus, be important if azithromycin is used for prophylaxis. In summary, azithromycin effectively prevented experimenit is not surprising that only a portion of the biopsies was culture positive.
tal chancroid for nearly 2 months. In areas of Africa where HIV and STDs are endemic, provision of STD treatment serWe measured the concentrations of ciprofloxacin and azithromycin in PBMC weekly after the administration of vices reduces HIV seroconversion rates by 40% [31]. Our chemoprophylaxis trial provides a rationale for field trials in areas the drugs. Azithromycin and ciprofloxacin are concentrated intracellularly [14, 18 -20] . PBMC were chosen as a surroendemic for chancroid. In such areas, core groups could be given azithromycin on a monthly or bimonthly basis in an gate marker for tissue since they are conveniently and reproducibly obtained for sequential evaluations. Determination effort to eliminate chancroid and other STDs and to reduce HIV seroconversion rates. of the drug concentration in resident skin cells, such as fibroblasts or keratinocytes, may have provided a more relevant measurement, but acquisition of weekly skin biopsies
